Vanda Pharmaceuticals (VNDA) Enterprise Value (2016 - 2025)
Vanda Pharmaceuticals (VNDA) has disclosed Enterprise Value for 17 consecutive years, with -$263.8 million as the latest value for Q4 2025.
- Quarterly Enterprise Value rose 29.57% to -$263.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$263.8 million through Dec 2025, up 29.57% year-over-year, with the annual reading at -$263.8 million for FY2025, 29.57% up from the prior year.
- Enterprise Value hit -$263.8 million in Q4 2025 for Vanda Pharmaceuticals, up from -$293.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$263.8 million in Q4 2025 to a low of -$501.5 million in Q1 2023.
- Historically, Enterprise Value has averaged -$401.8 million across 5 years, with a median of -$395.3 million in 2021.
- Biggest five-year swings in Enterprise Value: decreased 21.08% in 2021 and later grew 29.57% in 2025.
- Year by year, Enterprise Value stood at -$432.8 million in 2021, then fell by 7.87% to -$466.9 million in 2022, then increased by 16.83% to -$388.3 million in 2023, then rose by 3.51% to -$374.6 million in 2024, then increased by 29.57% to -$263.8 million in 2025.
- Business Quant data shows Enterprise Value for VNDA at -$263.8 million in Q4 2025, -$293.8 million in Q3 2025, and -$325.6 million in Q2 2025.